NOXXON Pharma
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Max-dohrn-str. 8-10, Berlin, Berlin, 105...Phone Number
+49 307262470Website
www.noxxon.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NOXXON Pharma
Founded in 1997, NOXXON Pharma is a clinical-stage biopharmaceutical company, that focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company is headquartered in Berlin, Germany.Explore more
NOXXON Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NOXXON Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at NOXXON Pharma
Funding: Get notified immidiatlly once NOXXON Pharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
NOXXON Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NOXXON Pharma recently announced quarterly report
Click to see if NOXXON Pharma had a recent Job posting/layoffs
Check out if NOXXON Pharma is spiking on competitors!
Check if NOXXON Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NOXXON Pharma launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
NOXXON Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NOXXON Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NOXXON Pharma.
NOXXON Pharma financials insights
Gather financial insights about NOXXON Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2000
Series B
$23.6M
2010
Series D
$40.4M
2020
Share Placement
$557K
Debt
$15.3M
2021
Stock Offering
$7.8M
Stock Offering
$1.4M
2022
Share Placement
$2.6M
NOXXON Pharma Tech Stack
A closer look at the technologies used by NOXXON Pharma
See more technologies
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
NOXXON Pharma News & Media
NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASCO Annual Meeting and Invitation to a Dedicated KOL Event
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces publication of the abstract of its poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which will take place in Chicago, Illinois, US, from June 3 to June 7, 2022. The poster presentation entitled “Radiotherapy and olaptesed pegol (NOXXON Amends Equity-Linked Facility With Atlas
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the third amendment to its agreement with Atlas Special Opportunities, LLC (ASO) which increases and equilibrizes all remaining tranches to €1.08 million, adjusts the conversion conditions to those in the original agreement of April 2020 and allows NOXXON to draw twNOXXON Appoints Leading Brain Cancer Experts to Scientific Advisory Board
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the appointment of two leading brain cancer experts to its Scientific Advisory Board (SAB). Prof. Monika Hegi and Dr. Michael Lim and will complement the current SAB and provide strategic and scientific counsel to NOXXON’s lead NOX-A12 program in brain cancer (gliobNOXXON Announces €2.375 Million Financing Under Agreement With Atlas
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has drawn down additional financing tranches from its financing agreement with Atlas Special Opportunities, LLC (ASO), for a total consideration of €2,375,000, and issued 2,419 convertible bonds (including 44 convertible bonds issued in relation to the trans
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NOXXON Pharma
Sign Up For FreeTo access detailed company insights
Founded in 1997, NOXXON Pharma is a clinical-stage biopharmaceutical company, that focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company is headquartered in Berlin, Germany.... Read More
